{"title":"获得","authors":"D. deSá","doi":"10.5040/9781474284776.386","DOIUrl":null,"url":null,"abstract":"Clinical Science, ABSTRACT: Background: Opioid antagonists may mitigate medication-associated weight gain and/or metabolic dys-regulation. ENLIGHTEN-2 evaluated a combination of olanzapine and the opioid antagonist samidorphan (OLZ/SAM) vs olanzapine for","PeriodicalId":390519,"journal":{"name":"Instrumentation Fundamentals for Process Control","volume":"5 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2019-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Gain\",\"authors\":\"D. deSá\",\"doi\":\"10.5040/9781474284776.386\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Clinical Science, ABSTRACT: Background: Opioid antagonists may mitigate medication-associated weight gain and/or metabolic dys-regulation. ENLIGHTEN-2 evaluated a combination of olanzapine and the opioid antagonist samidorphan (OLZ/SAM) vs olanzapine for\",\"PeriodicalId\":390519,\"journal\":{\"name\":\"Instrumentation Fundamentals for Process Control\",\"volume\":\"5 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-10-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Instrumentation Fundamentals for Process Control\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.5040/9781474284776.386\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Instrumentation Fundamentals for Process Control","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5040/9781474284776.386","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Clinical Science, ABSTRACT: Background: Opioid antagonists may mitigate medication-associated weight gain and/or metabolic dys-regulation. ENLIGHTEN-2 evaluated a combination of olanzapine and the opioid antagonist samidorphan (OLZ/SAM) vs olanzapine for
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
